Despite the pro-survival role of NF-κB in DLBCL, activation of NF-κB has been reported to be disadvantageous in MYC positive BL consistent with our data, supporting a role of miR-378a-3p-dependent repression of IRAK4 in limiting the activation of NF-κB [44,45]. The gene discussed is NFKB1; the disease is Burkitt lymphoma.